Develop and evaluate novel drug delivery system of valsartan for treatment of Hypertension: A review

Chandan Rajesh  Sindhi; Pankaj Motilal  Chaudhari; Anup Mukund  Akarte; Kalpesh Shankant  Wagh; Prakash Hiraman  Pati

doi:10.30574/gscbps.2021.15.3.0179

Authors

Chandan Rajesh Sindhi Department of Pharmaceutics, Kisan Vidya Prasarak Sansthas, Institute of Pharmaceutical Education, Boradi, Shirpur, Dist.- Dhule 425428, Maharashtra, India.
Pankaj Motilal Chaudhari Department of Pharmacology, Kisan Vidya Prasarak Sansthas, Institute of Pharmaceutical Education, Boradi, Shirpur, Dist.- Dhule 425428, Maharashtra, India.
Anup Mukund Akarte Department of Pharmaceutics, Kisan Vidya Prasarak Sansthas, Institute of Pharmaceutical Education, Boradi, Shirpur, Dist.- Dhule 425428, Maharashtra, India.
Kalpesh Shankant Wagh Department of Pharmaceutics, Kisan Vidya Prasarak Sansthas, Institute of Pharmaceutical Education, Boradi, Shirpur, Dist.- Dhule 425428, Maharashtra, India.
Prakash Hiraman Pati Department of Pharmacology, Kisan Vidya Prasarak Sansthas, Institute of Pharmaceutical Education, Boradi, Shirpur, Dist.- Dhule 425428, Maharashtra, India.

DOI:

https://doi.org/10.30574/gscbps.2021.15.3.0179

Keywords:

Sustained, Hypertension, Cellulose, Linearity, Polymers, Valsartan

Abstract

The sustained release tablets were formulated by using the combination of various release retardant polymers/excipient. The polymers used were hydroxypropyl methylcellulose, Micro Crystalline Cellulose and Sodium starch glycolate. The present investigation involves formulation and evaluation of sustained release tablets of Valsartan with a view to prolong the drug release in the gastrointestinal tract and consequently into the plasma. It showed good linearity and reproducibility which also indicated the analytical method used in the present study to be suitable for the estimation of the drug candidates in different dissolution media. Evaluation parameters such as thickness and diameter, weight variation and drug content uniformity test. The observation for all above evaluation parameters indicate that the values are within the IP specified limits. Thus, on the basis of our research findings it could be concluded that the performance of the developed sustained release tablets was found to be promising for the treatment of hypertension.

Metrics

Metrics Loading ...

References

AG Thombre, LE Appel, MB Chidlaw, PD Daugherity, F Dumont, LAF Evans, SC Sutton. Osmotic drug delivery using swellable core technology. Journal of Controlled Release. 2004; 94: 75-89.

Abdel Naser Zaid, Rita Cortesi, Aiman Qaddomi, Saed Khammash. Formulation and Bioequivalence of Two Valsartan Tablets after a Single Oral Administration. Sci Pharm. 2011; 79: 123–135.

Acharya KR, Sturrock ED, Riordan JF, Ehlers MRW. Nat. Rev. Drug Discovery. 2003; 2: 891–902.

Afsar C. Shaikh, Sayyed Nazim, Shaikh Siraj, Tarique Khan, M. Siddik Patel, Mohammad Zameeruddin, Arshad Shaikh. Formulation and evaluation of sustained release tablets of aceclofenac using hydrophilic matrix system. Int J Pharm Pharm Sci. 2011; 3(2): 145-148.

Agnivesh R, Shrivastava, Bhalchandra U, Kapadia J. Design optimization preparation and evaluation of dispersion granules of Valsartan and formulation into tablets. Curr Drug Deliver. 2009; (2): 28-37.

Agusti A. Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction: meta-analysis of randomized clinical trials. Drug Safety. 2003; 26: 895–908.

Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann Pharmacother. 1996; 30: 55–61.

Ankit B. Chaudhary, Rakesh K. Patel, Sunita A. Chaudhary, Krupa V. Gadhvi. Estimation of valsartan and hydrochlorothiazide in pharmaceutical dosage forms by absorption ratio method. 2010; 0976-4550.

Vendatraman S, Dava N, Chester A, Kleiner L. An Overview of Controlled Release Systems. In Handbook of Pharmaceutical Controlled Release technology. Wise, D.L. (ed). Marcel Dekker, New York. 2000; 435-445.

VH LEE, JR Robinson. in Sustained and Controlled Release Drug Delivery System, Marcel Dekker, New York. 1978; 71-78.

Pradhan Kishanta Kumar, Mishra Uma Shankar, Pattnaik Subasini, Panigrahi hanshyam, Pasa Gourishyam, Sahu Kanhu Charana. Stress Degradation Studies on Valsartan and Development of a Validated Method by UV Spectrophotometric in Bulk and Pharmaceutical Dosage Form. JPBMS. 2011; 8(02).

Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. J. Biol. Chem. 1993; 68: 24539–24542.

Muller P, Flesch G, de Gasparo M, Gasparini M, Howald H. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol. 1997; 52: 441–449.